31 May 2016 - New indication marks the third approval for Keytruda in Canada.

Merck announced today that Keytruda (pembrolizumab) received approval for the treatment of patients with unresectable or metastatic melanoma who have not received prior treatment with ipilimumab.

Keytruda is now the first and only anti-PD1 agent approved for first-line treatment regardless of BRAF mutation status.

For more details, go to: http://www.merck.ca/Assets/News/FINAL%20Merck%20Canada%20KEYTRUDA%20MEL%201L%20News%20Release%20-%20May%2031%202016%20-%20EN.pdf